MAY 20, 2020
11:15 AM EDT | APAC MAY 21, 2020 2:15 PM CST
Background: CDK4/6 inhibitors increase tumor immunogenicity in preclinical models of breast cancer and several trials combining CDK4/6 inhibitors and anti-PD1/PDL1 therapies are underway. Ho...